Loading...

Eric Small, MD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address1450 Third St
San Francisco CA 94158
Phone415-353-7095
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoPost-Doc Fellow/Scholar1991 Medicine (Cancer Research Institute)
    University of California, San FranciscoResidency

    Collapse Overview 
    Collapse Overview
    My interests lie in clinical and translational research in advanced prostate cancer, including trial design, and development of novel agents. I piloted the early trials targeting the androgen receptor in advanced prostate cancer, developing ketoconazole and contributing to an understanding of its mechanisms of activity and resistance. I subsequently was centrally involved with the development of two novel androgen signaling inhibitors, abiraterone acetate and apalutamide, from first in human studies to FDA approval.

    I have also been involved in the early application of immunotherapy to prostate cancer, developing sipuleucel T from first in human studies through FDA
    approval, and undertaking the first in human testing of ipilimumab, the first immune check point inhibitor to be clinically developed.

    Understanding the mechanisms of resistance in advanced prostate cancer has been a research focus. I was principal investigator of a $10 million multi-center Stand Up to Cancer (SU2C)/Prostate Cancer Foundation Dream Team Award undertaking deep genomic characterization of prostate cancer metastases, in order to elucidate patterns of resistance in abiraterone and/or enzalutamide
    treated patients. Important observations from this, and subsequent work have included unexpectedly high prevalence rates of treatment associated small cell/neuroendocrine prostate cancer (t-SCNC), as well key structural variants which contribute to progression of castration-resistant disease, observed in the largest Whole Genome Sequencing series to date of metastatic advanced prostate cancer specimens.

    I hold a number of leadership roles, serving as Leader of the UCSF Prostate Cancer Program, and as Deputy Director of the UCSF Helen Diller Family Comprehensive Cancer Center. I have served as Chief of the Division of Hematology and Oncology in the UCSF Department of Medicine for 10 years, and most recently have assumed the position of Chief Scientific Officer in the UCSF Helen Diller Family Comprehensive Cancer Center. Nationally, I serve on the ASCO Board of Directors, and chair a number of External Advisory Boards for other Cancer Centers.

    Throughout all of these activities, is a deep and abiding commitment to mentorship and support of the next generation of cancer clinicians and investigators.

    Collapse Research 
    Collapse Research Activities and Funding
    Cancer Center Support Grant
    NIH/NCI P30CA082103Aug 5, 1999 - Sep 29, 2012
    Role: Co-Investigator
    General Clinical Research Center
    NIH/NCRR M01RR000079Dec 1, 1974 - Sep 29, 2006
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites
    Collapse In The News
    Collapse Academic Senate

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2020 Jul 29. Guan X, Sun D, Lu E, Urrutia JA, Reiter RE, Rettig M, Evans CP, Lara P, Gleave M, Beer TM, Thomas GV, Huang J, Aggarwal RR, Quigley DA, Foye A, Chen WS, Youngren J, Weinstein AS, Stuart JM, Feng FY, Small EJ, Xia Z, Alumkal JJ. PMID: 32727885.
      View in: PubMed   Mentions:    Fields:    
    2. Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer. J Clin Oncol. 2020 Jul 24; JCO2000315. Eastham JA, Heller G, Halabi S, Monk JP, Beltran H, Gleave M, Evans CP, Clinton SK, Szmulewitz RZ, Coleman J, Hillman DW, Watt CR, George S, Sanda MG, Hahn OM, Taplin ME, Parsons JK, Mohler JL, Small EJ, Morris MJ. PMID: 32706639.
      View in: PubMed   Mentions:    Fields:    
    3. A Phase 1b/2a Study of the Pan-BET Bromodomain Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer. Clin Cancer Res. 2020 Jul 21. Aggarwal RR, Schweizer MT, Nanus DM, Pantuck AJ, Heath EI, Campeau E, Attwell S, Norek K, Snyder M, Bauman L, Lakhotia S, Feng FY, Small EJ, Abida W, Alumkal JJ. PMID: 32694156.
      View in: PubMed   Mentions:    Fields:    
    4. The DNA methylation landscape of advanced prostate cancer. Nat Genet. 2020 Jul 13. Zhao SG, Chen WS, Li H, Foye A, Zhang M, Sjöström M, Aggarwal R, Playdle D, Liao A, Alumkal JJ, Das R, Chou J, Hua JT, Barnard TJ, Bailey AM, Chow ED, Perry MD, Dang HX, Yang R, Moussavi-Baygi R, Zhang L, Alshalalfa M, Laura Chang S, Houlahan KE, Shiah YJ, Beer TM, Thomas G, Chi KN, Gleave M, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Yvonne Kim M, Fong L, Spratt DE, Morgan TM, Bose R, Huang FW, Li H, Chesner L, Shenoy T, Goodarzi H, Asangani IA, Sandhu S, Lang JM, Mahajan NP, Lara PN, Evans CP, Febbo P, Batzoglou S, Knudsen KE, He HH, Huang J, Zwart W, Costello JF, Luo J, Tomlins SA, Wyatt AW, Dehm SM, Ashworth A, Gilbert LA, Boutros PC, Farh K, Chinnaiyan AM, Maher CA, Small EJ, Quigley DA, Feng FY. PMID: 32661416.
      View in: PubMed   Mentions:    Fields:    
    5. Down-regulation of ADRB2 expression is associated with small cell neuroendocrine prostate cancer and adverse clinical outcomes in castration-resistant prostate cancer. Urol Oncol. 2020 Jul 02. Kwon DH, Zhang L, Quigley DA, Foye A, Chen WS, Wong CK, Feng FY, Bailey A, Huang J, Stuart JM, Friedl V, Weinstein AS, Beer TM, Alumkal JJ, Rettig M, Gleave M, Lara PN, Thomas GV, Li P, Lui A, Small EJ, Aggarwal RR. PMID: 32624423.
      View in: PubMed   Mentions:    Fields:    
    6. Efficacy and Safety Exposure-Response Relationships of Apalutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2020 Sep 01; 26(17):4460-4467. Perez-Ruixo C, Ackaert O, Ouellet D, Chien C, Uemura H, Olmos D, Mainwaring P, Lee JY, Yu MK, Perez-Ruixo JJ, Smith MR, Small EJ. PMID: 32561663.
      View in: PubMed   Mentions:    Fields:    
    7. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance. Proc Natl Acad Sci U S A. 2020 Jun 02; 117(22):12315-12323. Alumkal JJ, Sun D, Lu E, Beer TM, Thomas GV, Latour E, Aggarwal R, Cetnar J, Ryan CJ, Tabatabaei S, Bailey S, Turina CB, Quigley DA, Guan X, Foye A, Youngren JF, Urrutia J, Huang J, Weinstein AS, Friedl V, Rettig M, Reiter RE, Spratt DE, Gleave M, Evans CP, Stuart JM, Chen Y, Feng FY, Small EJ, Witte ON, Xia Z. PMID: 32424106.
      View in: PubMed   Mentions: 1     Fields:    
    8. Clinical and genomic characterization of Low PSA Secretors: a unique subset of metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2020 Apr 14. Aggarwal R, Romero GR, Friedl V, Weinstein A, Foye A, Huang J, Feng F, Stuart JM, Small EJ. PMID: 32286548.
      View in: PubMed   Mentions: 1     Fields:    
    9. Does the COVID-19 outbreak identify a broader need for an urgent transformation of cancer clinical trials research? Contemp Clin Trials. 2020 05; 92:105997. Borno HT, Small EJ. PMID: 32272172.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsPHPublic Health
    10. Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. Prostate Cancer Prostatic Dis. 2020 Sep; 23(3):517-526. Sartor O, Armstrong AJ, Ahaghotu C, McLeod DG, Cooperberg MR, Penson DF, Kantoff PW, Vogelzang NJ, Hussain A, Pieczonka CM, Shore ND, Quinn DI, Small EJ, Heath EI, Tutrone RF, Schellhammer PF, Harmon M, Chang NN, Sheikh NA, Brown B, Freedland SJ, Higano CS. PMID: 32111923.
      View in: PubMed   Mentions: 1     Fields:    
    11. Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. JNCI Cancer Spectr. 2020 Apr; 4(2):pkaa003. Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, De Bono JS, Araujo JC, Logothetis C, Eisenberger MA, Quinn DI, Fizazi K, Morris MJ, Higano CS, Tannock IF, Small EJ, Kelly WK. PMID: 32368717.
      View in: PubMed   Mentions:
    12. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. Eur Urol. 2020 Apr; 77(4):508-547. Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano CTS, Hofman MS, Hussain M, James N, Kanesvaran R, Kantoff P, Khauli RB, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Reiter RE, Roach M, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Small E, Smith M, Soule H, Sternberg CN, Steuber T, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tombal B, Türkeri L, van Oort I, Zapatero A, Omlin A. PMID: 32001144.
      View in: PubMed   Mentions: 3     Fields:    
    13. Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial. JAMA. 2020 01 14; 323(2):140-148. Parsons JK, Zahrieh D, Mohler JL, Paskett E, Hansel DE, Kibel AS, Liu H, Seisler DK, Natarajan L, White M, Hahn O, Taylor J, Hartman SJ, Stroup SP, Van Veldhuizen P, Hall L, Small EJ, Morris MJ, Pierce JP, Marshall J. PMID: 31935026.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    14. Germline polymorphisms associated with impaired survival outcomes and somatic tumor alterations in advanced prostate cancer. Prostate Cancer Prostatic Dis. 2020 06; 23(2):316-323. Chen WS, Feng EL, Aggarwal R, Foye A, Beer TM, Alumkal JJ, Gleave M, Chi KN, Reiter RE, Rettig MB, Evans CP, Small EJ, Sharifi N, Zhao SG. PMID: 31745256.
      View in: PubMed   Mentions: 1     Fields:    
    15. A step towards equitable clinical trial recruitment: a protocol for the development and preliminary testing of an online prostate cancer health information and clinical trial matching tool. Pilot Feasibility Stud. 2019; 5:123. Borno HT, Bakke BM, Kaplan C, Hebig-Prophet A, Chao J, Kim YJ, Yeager J, Cinar P, Small E, Boscardin C, Gonzales R. PMID: 31720002.
      View in: PubMed   Mentions:
    16. Relationship Between Metastasis-free Survival and Overall Survival in Patients With Nonmetastatic Castration-resistant Prostate Cancer. Clin Genitourin Cancer. 2020 04; 18(2):e180-e189. Smith MR, Mehra M, Nair S, Lawson J, Small EJ. PMID: 31980408.
      View in: PubMed   Mentions:    Fields:    
    17. Hyperpolarized 13C-pyruvate MRI detects real-time metabolic flux in prostate cancer metastases to bone and liver: a clinical feasibility study. Prostate Cancer Prostatic Dis. 2020 06; 23(2):269-276. Chen HY, Aggarwal R, Bok RA, Ohliger MA, Zhu Z, Lee P, Gordon JW, van Criekinge M, Carvajal L, Slater JB, Larson PEZ, Small EJ, Kurhanewicz J, Vigneron DB. PMID: 31685983.
      View in: PubMed   Mentions: 2     Fields:    
    18. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. Ann Oncol. 2019 11 01; 30(11):1813-1820. Small EJ, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith AA, Zhang K, Lopez-Gitlitz A, Smith MR. PMID: 31560066.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    19. How current reporting practices may mask differences: A call for examining cancer-specific demographic enrollment patterns in cancer treatment clinical trials. Contemp Clin Trials Commun. 2019 Dec; 16:100476. Borno HT, Small EJ, Zhang L, DeRouen MC, Griffin A, McGuire J, Ryan CJ, Hiatt RA, Kaplan CP. PMID: 31872154.
      View in: PubMed   Mentions:
    20. Clinical Outcomes in Cyclin-dependent Kinase 12 Mutant Advanced Prostate Cancer. Eur Urol. 2020 Mar; 77(3):333-341. Reimers MA, Yip SM, Zhang L, Cieslik M, Dhawan M, Montgomery B, Wyatt AW, Chi KN, Small EJ, Chinnaiyan AM, Alva AS, Feng FY, Chou J. PMID: 31640893.
      View in: PubMed   Mentions: 3     Fields:    
    21. Ethnic disparities among men with prostate cancer undergoing germline testing. Urol Oncol. 2020 03; 38(3):80.e1-80.e7. Kwon DH, Borno HT, Cheng HH, Zhou AY, Small EJ. PMID: 31630993.
      View in: PubMed   Mentions: 2     Fields:    
    22. Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019 12 15; 25(24):7448-7454. Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, Cheng S, Maurer T, Herrmann K, Eiber M, Hadaschik B. PMID: 31511295.
      View in: PubMed   Mentions: 2     Fields:    
    23. Cabozantinib Versus Sunitinib for Untreated Patients with Advanced Renal Cell Carcinoma of Intermediate or Poor Risk: Subgroup Analysis of the Alliance A031203 CABOSUN trial. Oncologist. 2019 11; 24(11):1497-1501. George DJ, Hessel C, Halabi S, Michaelson MD, Hahn O, Walsh M, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, Morris MJ, Choueiri TK. PMID: 31399500.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    24. The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. Clin Cancer Res. 2019 12 01; 25(23):6916-6924. Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker A, Arnold J, Hecht T, Wicha M, Sears R, Rowley D, White R, Gulley JL, Lee J, Diaz Meco M, Small EJ, Shen M, Knudsen K, Goodrich DW, Lotan T, Zoubeidi A, Sawyers CL, Rudin CM, Loda M, Thompson T, Rubin MA, Tawab-Amiri A, Dahut W, Nelson PS. PMID: 31363002.
      View in: PubMed   Mentions: 8     Fields:    
    25. Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors. Future Oncol. 2019 Jul; 15(20):2337-2348. Desai A, Small EJ. PMID: 31184937.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    26. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. JAMA Oncol. 2019 Jun 01; 5(6):856-863. Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, Nguyen HG, Reiter RE, Rettig MB, Okamoto S, Emmett L, Zacho HD, Ilhan H, Wetter A, Rischpler C, Schoder H, Burger IA, Gartmann J, Smith R, Small EJ, Slavik R, Carroll PR, Herrmann K, Czernin J, Hope TA. PMID: 30920593.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    27. Androgen decline and survival during docetaxel therapy in metastatic castration resistant prostate cancer (mCRPC). Prostate Cancer Prostatic Dis. 2020 03; 23(1):66-73. Ryan CJ, Dutta S, Kelly WK, Russell C, Small EJ, Morris MJ, Taplin ME, Halabi S. PMID: 31053766.
      View in: PubMed   Mentions: 1     Fields:    
    28. Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019 05 01; 17(5):479-505. Mohler JL, Antonarakis ES, Armstrong AJ, D'Amico AV, Davis BJ, Dorff T, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Ippolito JE, Kane CJ, Kuettel MR, Lang JM, McKenney J, Netto G, Penson DF, Plimack ER, Pow-Sang JM, Pugh TJ, Richey S, Roach M, Rosenfeld S, Schaeffer E, Shabsigh A, Small EJ, Spratt DE, Srinivas S, Tward J, Shead DA, Freedman-Cass DA. PMID: 31085757.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    29. Germline and Somatic Mutations in Prostate Cancer for the Clinician. J Natl Compr Canc Netw. 2019 05 01; 17(5):515-521. Cheng HH, Sokolova AO, Schaeffer EM, Small EJ, Higano CS. PMID: 31085765.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    30. Incidentally Detected Oropharyngeal Squamous Cell Carcinoma on 18F-Fluciclovine PET/CT. Clin Nucl Med. 2019 May; 44(5):e367-e369. Raghavan K, Wen KW, Small EJ, Ha P, Flavell RR. PMID: 30829856.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    31. Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. Clin Cancer Res. 2019 Jul 15; 25(14):4290-4299. Chen WS, Alshalalfa M, Zhao SG, Liu Y, Mahal BA, Quigley DA, Wei T, Davicioni E, Rebbeck TR, Kantoff PW, Maher CA, Knudsen KE, Small EJ, Nguyen PL, Feng FY. PMID: 31010837.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    32. Genomic Drivers of Poor Prognosis and Enzalutamide Resistance in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019 11; 76(5):562-571. Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, Quigley DA, Foye A, Playdle D, Huang J, Lloyd P, Lu E, Sun D, Guan X, Rettig M, Gleave M, Evans CP, Youngren J, True L, Lara P, Kothari V, Xia Z, Chi KN, Reiter RE, Maher CA, Feng FY, Small EJ, Alumkal JJ. PMID: 30928160.
      View in: PubMed   Mentions: 8     Fields:    
    33. Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. Mol Cancer Res. 2019 06; 17(6):1235-1240. Aggarwal RR, Quigley DA, Huang J, Zhang L, Beer TM, Rettig MB, Reiter RE, Gleave ME, Thomas GV, Foye A, Playdle D, Lloyd P, Chi KN, Evans CP, Lara PN, Feng FY, Alumkal JJ, Small EJ. PMID: 30918106.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    34. MEK-ERK signaling is a therapeutic target in metastatic castration resistant prostate cancer. Prostate Cancer Prostatic Dis. 2019 12; 22(4):531-538. Nickols NG, Nazarian R, Zhao SG, Tan V, Uzunangelov V, Xia Z, Baertsch R, Neeman E, Gao AC, Thomas GV, Howard L, De Hoedt AM, Stuart J, Goldstein T, Chi K, Gleave ME, Graff JN, Beer TM, Drake JM, Evans CP, Aggarwal R, Foye A, Feng FY, Small EJ, Aronson WJ, Freedland SJ, Witte ON, Huang J, Alumkal JJ, Reiter RE, Rettig MB. PMID: 30804427.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    35. Intertumoral Heterogeneity of 18F-FDG and 68Ga-PSMA Uptake in Prostate Cancer Pulmonary Metastases. Clin Nucl Med. 2019 Jan; 44(1):e28-e32. Perez PM, Hope TA, Behr SC, van Zante A, Small EJ, Flavell RR. PMID: 30394930.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    36. Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. J Clin Oncol. 2019 02 10; 37(5):403-410. Halabi S, Dutta S, Tangen CM, Rosenthal M, Petrylak DP, Thompson IM, Chi KN, Araujo JC, Logothetis C, Quinn DI, Fizazi K, Morris MJ, Eisenberger MA, George DJ, De Bono JS, Higano CS, Tannock IF, Small EJ, Kelly WK. PMID: 30576268.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    37. Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. Clin Cancer Res. 2019 04 15; 25(8):2450-2457. Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, Quigley DA, Dang HX, Barnard TJ, Mahal BA, Gibb EA, Liu Y, Davicioni E, Duska LR, Posadas EM, Jolly S, Spratt DE, Nguyen PL, Maher CA, Small EJ, Feng FY. PMID: 30573691.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    38. Reply to A. Dalla Volta et al. J Clin Oncol. 2019 02 01; 37(4):351-352. Aggarwal R, Huang J, Alumkal J, Feng FY, Zhang L, Stuart JM, Small EJ. PMID: 30557523.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    39. Phase I Study of CTT1057, an 18F-Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate-Specific Membrane Antigen in Prostate Cancer. J Nucl Med. 2019 07; 60(7):910-916. Behr SC, Aggarwal R, VanBrocklin HF, Flavell RR, Gao K, Small EJ, Blecha J, Jivan S, Hope TA, Simko JP, Kurhanewicz J, Noworolski SM, Korn NJ, De Los Santos R, Cooperberg MR, Carroll PR, Nguyen HG, Greene KL, Langton-Webster B, Berkman CE, Seo Y. PMID: 30464040.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    40. Apalutamide and its use in the treatment of prostate cancer. Future Oncol. 2019 Feb; 15(6):591-599. Borno HT, Small EJ. PMID: 30426794.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    41. Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials. Ther Adv Urol. 2018 Dec; 10(12):445-454. Koshkin VS, Small EJ. PMID: 30574205.
      View in: PubMed   Mentions:
    42. Management of recurrent prostate cancer after radiotherapy: long-term results from CALGB 9687 (Alliance), a prospective multi-institutional salvage prostatectomy series. Prostate Cancer Prostatic Dis. 2019 05; 22(2):309-316. Mohler JL, Halabi S, Ryan ST, Al-Daghmin A, Sokoloff MH, Steinberg GD, Sanford BL, Eastham JA, Walther PJ, Morris MJ, Small EJ. PMID: 30385835.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    43. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 10 18; 175(3):889. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. PMID: 30340047.
      View in: PubMed   Mentions: 6     Fields:    
    44. Itraconazole as a Noncastrating Treatment for Biochemically Recurrent Prostate Cancer: A Phase 2 Study. Clin Genitourin Cancer. 2019 Feb; 17(1):e92-e96. Lee M, Hong H, Kim W, Zhang L, Friedlander TW, Fong L, Lin AM, Small EJ, Wei XX, Rodvelt TJ, Miralda B, Stocksdale B, Ryan CJ, Aggarwal R. PMID: 30327180.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    45. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 10; 19(10):1404-1416. Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, Graff JN, McQuarrie K, Li S, Hudgens S, Lawson J, Lopez-Gitlitz A, Yu MK, Smith MR, Small EJ. PMID: 30213449.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    46. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight. 2018 09 06; 3(17). Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B. PMID: 30185663.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    47. A bilingual, Internet-based, targeted advertising campaign for prostate cancer clinical trials: Assessing the feasibility, acceptability, and efficacy of a novel recruitment strategy. Contemp Clin Trials Commun. 2018 Dec; 12:60-67. Kaplan CP, Siegel A, Leykin Y, Palmer NR, Borno H, Bielenberg J, Livaudais-Toman J, Ryan C, Small EJ. PMID: 30272035.
      View in: PubMed   Mentions:
    48. DNA Repair Gene Alterations and PARP Inhibitor Response in Patients With Metastatic Castration-Resistant Prostate Cancer. J Natl Compr Canc Netw. 2018 08; 16(8):933-937. Lu E, Thomas GV, Chen Y, Wyatt AW, Lloyd P, Youngren J, Quigley D, Bergan R, Bailey S, Beer TM, Feng FY, Small EJ, Alumkal JJ. PMID: 30099369.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    49. Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. Cell. 2018 07 26; 174(3):758-769.e9. Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY. PMID: 30033370.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    50. Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. J Clin Oncol. 2018 08 20; 36(24):2492-2503. Aggarwal R, Huang J, Alumkal JJ, Zhang L, Feng FY, Thomas GV, Weinstein AS, Friedl V, Zhang C, Witte ON, Lloyd P, Gleave M, Evans CP, Youngren J, Beer TM, Rettig M, Wong CK, True L, Foye A, Playdle D, Ryan CJ, Lara P, Chi KN, Uzunangelov V, Sokolov A, Newton Y, Beltran H, Demichelis F, Rubin MA, Stuart JM, Small EJ. PMID: 29985747.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCellsCTClinical Trials
    51. Apalutamide and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018 06 28; 378(26):2542. Smith MR, Yu MK, Small EJ. PMID: 29949495.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    52. Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. Clin Cancer Res. 2018 10 01; 24(19):4662-4671. Antonarakis ES, Small EJ, Petrylak DP, Quinn DI, Kibel AS, Chang NN, Dearstyne E, Harmon M, Campogan D, Haynes H, Vu T, Sheikh NA, Drake CG. PMID: 29858218.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    53. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. Eur Urol Oncol. 2018 05; 1(1):78-82. Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, Cooperberg M, Evans MJ, Hope T. PMID: 31100231.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    54. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018 05; 94:115-125. Choueiri TK, Hessel C, Halabi S, Sanford B, Michaelson MD, Hahn O, Walsh M, Olencki T, Picus J, Small EJ, Dakhil S, Feldman DR, Mangeshkar M, Scheffold C, George D, Morris MJ. PMID: 29550566.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    55. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018 Apr 12; 378(15):1408-1418. Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, Small EJ. PMID: 29420164.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCTClinical Trials
    56. Clinical Variables Associated With Overall Survival in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Sipuleucel-T Immunotherapy. Clin Genitourin Cancer. 2018 06; 16(3):184-190.e2. Wei XX, Perry J, Chang E, Zhang L, Hiatt RA, Ryan CJ, Small EJ, Fong L. PMID: 29352713.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    57. Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials. Cancer. 2018 04 01; 124(7):1383-1390. Atkins KM, Chen MH, Wu J, Renshaw AA, Loffredo M, Kantoff PW, Small EJ, D'Amico AV. PMID: 29266181.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    58. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer. J Natl Cancer Inst. 2017 Dec 01; 109(12). Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, Foye A, Lloyd P, Nykter M, Beer TM, Alumkal JJ, Thomas GV, Reiter RE, Rettig MB, Evans CP, Gao AC, Chi KN, Small EJ, Gleave ME. PMID: 29206995.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    59. Optimal MRI sequences for 68Ga-PSMA-11 PET/MRI in evaluation of biochemically recurrent prostate cancer. EJNMMI Res. 2017 Sep 19; 7(1):77. Lake ST, Greene KL, Westphalen AC, Behr SC, Zagoria R, Small EJ, Carroll PR, Hope TA. PMID: 28929350.
      View in: PubMed   Mentions:
    60. Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the LATITUDE and STAMPEDE Studies. Cancer Cell. 2017 09 11; 32(3):392. Small EJ. PMID: 28898699.
      View in: PubMed   Mentions: 2     Fields:    
    61. Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the LATITUDE and STAMPEDE Studies. Cancer Cell. 2017 07 10; 32(1):6-8. Small EJ. PMID: 28697343.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    62. Molecular Testing in Patients With Castration-Resistant Prostate Cancer and Its Impact on Clinical Decision Making. JCO Precis Oncol. 2017; 1. Tao DL, Bailey S, Beer TM, Foss E, Beckett B, Fung A, Foster BR, Guimaraes A, Cetnar JP, Graff JN, Eilers KM, Small EJ, Corless CL, Thomas GV, Alumkal JJ. PMID: 31650098.
      View in: PubMed   Mentions:
    63. Emerging Categories of Disease in Advanced Prostate Cancer and Their Therapeutic Implications. Oncology (Williston Park). 2017 06 15; 31(6):467-74. Aggarwal RR, Feng FY, Small EJ. PMID: 28620903.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    64. Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Mol Cancer Res. 2017 09; 15(9):1221-1229. Aggarwal R, Behr SC, Paris PL, Truillet C, Parker MFL, Huynh LT, Wei J, Hann B, Youngren J, Huang J, Premasekharan G, Ranatunga N, Chang E, Gao KT, Ryan CJ, Small EJ, Evans MJ. PMID: 28592703.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    65. High-Dose Abiraterone Acetate in Men With Castration Resistant Prostate Cancer. Clin Genitourin Cancer. 2017 12; 15(6):733-741.e1. Friedlander TW, Graff JN, Zejnullahu K, Anantharaman A, Zhang L, Paz R, Premasekharan G, Russell C, Huang Y, Kim W, Aggarwal RR, Lin AM, Fong L, Alumkal JJ, Beer TM, Sharifi N, Alyamani M, Dittamore R, Small EJ, Paris PL, Ryan CJ. PMID: 28655452.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    66. Tackling non-metastatic castration-resistant prostate cancer: special considerations in treatment. Expert Rev Anticancer Ther. 2017 07; 17(7):625-633. Anantharaman A, Small EJ. PMID: 28532278.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    67. CT-Guided Bone Biopsies in Metastatic Castration-Resistant Prostate Cancer: Factors Predictive of Maximum Tumor Yield. J Vasc Interv Radiol. 2017 Aug; 28(8):1073-1081.e1. Holmes MG, Foss E, Joseph G, Foye A, Beckett B, Motamedi D, Youngren J, Thomas GV, Huang J, Aggarwal R, Alumkal JJ, Beer TM, Small EJ, Link TM. PMID: 28549709.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    68. Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. BJU Int. 2018 04; 121(4):534-539. Parsons JK, Pierce JP, Mohler J, Paskett E, Jung SH, Morris MJ, Small E, Hahn O, Humphrey P, Taylor J, Marshall J. PMID: 28437029.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCTClinical Trials
    69. Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med. 2017 12; 58(12):1956-1961. Hope TA, Aggarwal R, Chee B, Tao D, Greene KL, Cooperberg MR, Feng F, Chang A, Ryan CJ, Small EJ, Carroll PR. PMID: 28522741.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    70. Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors. Cancer Discov. 2017 09; 7(9):999-1005. Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, Aggarwal R, Kim W, Lu E, Schwartzman J, Beja K, Annala M, Das R, Diolaiti M, Pritchard C, Thomas G, Tomlins S, Knudsen K, Lord CJ, Ryan C, Youngren J, Beer TM, Ashworth A, Small EJ, Feng FY. PMID: 28450426.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    71. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. 2017 07; 72(1):10-13. Smith MR, Saad F, Rathkopf DE, Mulders PFA, de Bono JS, Small EJ, Shore ND, Fizazi K, Kheoh T, Li J, De Porre P, Todd MB, Yu MK, Ryan CJ. PMID: 28314611.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    72. Androgen receptor amplification is concordant between circulating tumor cells and biopsies from men undergoing treatment for metastatic castration resistant prostate cancer. Oncotarget. 2017 Sep 22; 8(42):71447-71455. Podolak J, Eilers K, Newby T, Slottke R, Tucker E, Olson SB, Lue HW, Youngren J, Aggarwal R, Small EJ, Graff JN, Alumkal JJ, Beer TM, Thomas GV. PMID: 29069718.
      View in: PubMed   Mentions: 1     Fields:    
    73. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer. Eur Urol. 2017 07; 72(1):34-42. Annala M, Struss WJ, Warner EW, Beja K, Vandekerkhove G, Wong A, Khalaf D, Seppälä IL, So A, Lo G, Aggarwal R, Small EJ, Nykter M, Gleave ME, Chi KN, Wyatt AW. PMID: 28259476.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    74. A multicenter phase I study of cabazitaxel, mitoxantrone, and prednisone for chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: A department of defense prostate cancer clinical trials consortium study. Urol Oncol. 2017 04; 35(4):149.e7-149.e13. Aggarwal R, Bryce A, Ryan CJ, Harzstark A, Derleth C, Kim W, Friedlander T, Lin AM, Rodvelt-Bagchi T, Dhawan M, Zhang L, Lee M, Siebeneck E, Hough J, Small EJ. PMID: 28161323.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    75. A Feasibility Study Showing [68Ga]Citrate PET Detects Prostate Cancer. Mol Imaging Biol. 2016 12; 18(6):946-951. Behr SC, Aggarwal R, Seo Y, Aparici CM, Chang E, Gao KT, Tao DH, Small EJ, Evans MJ. PMID: 27184068.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    76. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. J Clin Oncol. 2017 02 20; 35(6):591-597. Choueiri TK, Halabi S, Sanford BL, Hahn O, Michaelson MD, Walsh MK, Feldman DR, Olencki T, Picus J, Small EJ, Dakhil S, George DJ, Morris MJ. PMID: 28199818.
      View in: PubMed   Mentions: 77     Fields:    Translation:HumansCTClinical Trials
    77. Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream Team. Eur Urol Focus. 2016 Dec; 2(5):469-471. Aggarwal R, Beer TM, Gleave M, Stuart JM, Rettig M, Evans CP, Youngren J, Alumkal JJ, Huang J, Thomas G, Witte O, Small EJ. PMID: 28723508.
      View in: PubMed   Mentions: 4     Fields:    
    78. Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunol Res. 2016 11; 4(11):948-958. Wei XX, Chan S, Kwek S, Lewis J, Dao V, Zhang L, Cooperberg MR, Ryan CJ, Lin AM, Friedlander TW, Rini B, Kane C, Simko JP, Carroll PR, Small EJ, Fong L. PMID: 27688020.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    79. 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. J Nucl Med. 2017 Jan; 58(1):81-84. Hope TA, Truillet C, Ehman EC, Afshar-Oromieh A, Aggarwal R, Ryan CJ, Carroll PR, Small EJ, Evans MJ. PMID: 27660139.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    80. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol. 2017 04; 71(4):656-664. de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PFA, Small EJ, Shore ND, Fizazi K, De Porre P, Kheoh T, Li J, Todd MB, Ryan CJ, Flaig TW. PMID: 27402060.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    81. An improved CTC isolation scheme for pairing with downstream genomics: Demonstrating clinical utility in metastatic prostate, lung and pancreatic cancer. Cancer Lett. 2016 09 28; 380(1):144-52. Premasekharan G, Gilbert E, Okimoto RA, Hamirani A, Lindquist KJ, Ngo VT, Roy R, Hough J, Edwards M, Paz R, Foye A, Sood R, Copren KA, Gubens M, Small EJ, Bivona TG, Collisson EA, Friedlander TW, Paris PL. PMID: 27343980.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    82. Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy. Clin Cancer Res. 2016 Oct 01; 22(19):4890-4900. Hertz DL, Owzar K, Lessans S, Wing C, Jiang C, Kelly WK, Patel J, Halabi S, Furukawa Y, Wheeler HE, Sibley AB, Lassiter C, Weisman L, Watson D, Krens SD, Mulkey F, Renn CL, Small EJ, Febbo PG, Shterev I, Kroetz DL, Friedman PN, Mahoney JF, Carducci MA, Kelley MJ, Nakamura Y, Kubo M, Dorsey SG, Dolan ME, Morris MJ, Ratain MJ, McLeod HL. PMID: 27143689.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCTClinical Trials
    83. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. J Clin Oncol. 2016 05 10; 34(14):1652-9. Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KN, de Bono J, Armstrong AJ, Eisenberger MA, Fandi A, Li S, Araujo JC, Logothetis CJ, Quinn DI, Morris MJ, Higano CS, Tannock IF, Small EJ. PMID: 26951312.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    84. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 Apr 20; 34(12):1402-18. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ. PMID: 26903579.
      View in: PubMed   Mentions: 119     Fields:    Translation:Humans
    85. Prospects for the use of ipilimumab in treating advanced prostate cancer. Expert Opin Biol Ther. 2016; 16(3):421-32. Wei XX, Fong L, Small EJ. PMID: 26698365.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    86. Prostate Cancer, Version 1.2016. J Natl Compr Canc Netw. 2016 01; 14(1):19-30. Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kawachi MH, Kuettel M, Lee RJ, Meeks JJ, Penson DF, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rosenfeld S, Schaeffer E, Skolarus TA, Small EJ, Sonpavde G, Srinivas S, Strope SA, Tward J, Shead DA, Freedman-Cass DA. PMID: 26733552.
      View in: PubMed   Mentions: 124     Fields:    Translation:Humans
    87. Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer. Can J Urol. 2015 Dec; 22(6):8048-55. Crawford ED, Petrylak DP, Higano CS, Kibel AS, Kantoff PW, Small EJ, Shore ND, Ferrari A. PMID: 26688132.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    88. Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. Eur Urol. 2016 05; 69(5):924-32. Bellmunt J, Kheoh T, Yu MK, Smith MR, Small EJ, Mulders PF, Fizazi K, Rathkopf DE, Saad F, Scher HI, Taplin ME, Davis ID, Schrijvers D, Protheroe A, Molina A, De Porre P, Griffin TW, de Bono JS, Ryan CJ, Oudard S. PMID: 26508309.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    89. Prostate Cancer Immunotherapy with Sipuleucel-T: Current Standards and Future Directions. Expert Rev Vaccines. 2015; 14(12):1529-41. Wei XX, Fong L, Small EJ. PMID: 26488270.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    90. Knowledge and attitudes regarding clinical trials and willingness to participate among prostate cancer patients. Contemp Clin Trials. 2015 Nov; 45(Pt B):443-448. Kaplan CP, Nápoles AM, Narine S, Gregorich S, Livaudais-Toman J, Nguyen T, Leykin Y, Roach M, Small EJ. PMID: 26435199.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    91. A Molecular Model for Predicting Overall Survival in Patients with Metastatic Clear Cell Renal Carcinoma: Results from CALGB 90206 (Alliance). EBioMedicine. 2015 Nov; 2(11):1814-20. Kim HL, Halabi S, Li P, Mayhew G, Simko J, Nixon AB, Small EJ, Rini B, Morris MJ, Taplin ME, George D. PMID: 26870806.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    92. Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Eur Urol. 2015 Oct; 68(4):570-7. Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin TA, De Porre P, Londhe A, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ. PMID: 25985882.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    93. Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. Cancer Immunol Res. 2015 Sep; 3(9):1008-16. Kwek SS, Lewis J, Zhang L, Weinberg V, Greaney SK, Harzstark AL, Lin AM, Ryan CJ, Small EJ, Fong L. PMID: 25968455.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCellsCTClinical Trials
    94. A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2015 Sep 01; 21(17):3862-9. Small EJ, Lance RS, Gardner TA, Karsh LI, Fong L, McCoy C, DeVries T, Sheikh NA, GuhaThakurta D, Chang N, Redfern CH, Shore ND. PMID: 25925891.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCellsCTClinical Trials
    95. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2015 May 15; 21(10):2315-24. Azad AA, Volik SV, Wyatt AW, Haegert A, Le Bihan S, Bell RH, Anderson SA, McConeghy B, Shukin R, Bazov J, Youngren J, Paris P, Thomas G, Small EJ, Wang Y, Gleave ME, Collins CC, Chi KN. PMID: 25712683.
      View in: PubMed   Mentions: 95     Fields:    Translation:HumansCells
    96. Progression-free survival: does a correlation with survival justify its role as a surrogate clinical endpoint? Cancer. 2015 Jun 01; 121(11):1906. Halabi S, Rini BI, Escudier B, Stadler WM, Small EJ. PMID: 25677867.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    97. Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. Clin Cancer Res. 2015 Aug 15; 21(16):3619-30. GuhaThakurta D, Sheikh NA, Fan LQ, Kandadi H, Meagher TC, Hall SJ, Kantoff PW, Higano CS, Small EJ, Gardner TA, Bailey K, Vu T, DeVries T, Whitmore JB, Frohlich MW, Trager JB, Drake CG. PMID: 25649018.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    98. Radiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results. J Clin Oncol. 2015 Apr 20; 33(12):1356-63. Morris MJ, Molina A, Small EJ, de Bono JS, Logothetis CJ, Fizazi K, de Souza P, Kantoff PW, Higano CS, Li J, Kheoh T, Larson SM, Matheny SL, Naini V, Burzykowski T, Griffin TW, Scher HI, Ryan CJ. PMID: 25624432.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCTClinical Trials
    99. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015 Feb; 16(2):152-60. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE. PMID: 25601341.
      View in: PubMed   Mentions: 195     Fields:    Translation:HumansCTClinical Trials
    100. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF. Clin Genitourin Cancer. 2015 Jun; 13(3):e191-8. Aggarwal RR, Beer TM, Weinberg VK, Higano C, Taplin ME, Ryan CJ, Lin AM, Alumkal J, Graff JN, Nordquist LT, Herrera I, Small EJ. PMID: 25557266.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    101. Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance). Cancer. 2015 Apr 01; 121(7):1025-31. Patel JN, Jiang C, Hertz DL, Mulkey FA, Owzar K, Halabi S, Ratain MJ, Friedman PN, Small EJ, Carducci MA, Mahoney JF, Kelley MJ, Morris MJ, Kelly WK, McLeod HL. PMID: 25417775.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    102. Sequential use of the androgen synthesis inhibitors ketoconazole and abiraterone acetate in castration-resistant prostate cancer and the predictive value of circulating androgens. Clin Cancer Res. 2014 Dec 15; 20(24):6269-76. Kim W, Zhang L, Wilton JH, Fetterly G, Mohler JL, Weinberg V, Morse A, Szmulewitz RZ, Friedlander TW, Fong L, Lin AM, Harzstark AL, Molina A, Small EJ, Ryan CJ. PMID: 25336698.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    103. Can targeting the androgen receptor in localized prostate cancer provide insights into why men with metastatic castration-resistant prostate cancer die? J Clin Oncol. 2014 Nov 20; 32(33):3689-91. Small EJ. PMID: 25311216.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    104. Small-cell/neuroendocrine prostate cancer: a growing threat? Oncology (Williston Park). 2014 Oct; 28(10):838-40. Aggarwal RR, Small EJ. PMID: 25323608.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    105. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. 2014 Nov; 106(11). Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, Simko J, Sheikh NA, Sims RB, Frohlich MW, Small EJ. PMID: 25255802.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCellsCTClinical Trials
    106. Reply to F. Valcamonico et al. J Clin Oncol. 2014 Nov 10; 32(32):3685. Smith MR, Halabi S, Small EJ. PMID: 25225438.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    107. A transient increase in eosinophils is associated with prolonged survival in men with metastatic castration-resistant prostate cancer who receive sipuleucel-T. Cancer Immunol Res. 2014 Oct; 2(10):988-99. McNeel DG, Gardner TA, Higano CS, Kantoff PW, Small EJ, Wener MH, Sims RB, DeVries T, Sheikh NA, Dreicer R. PMID: 25189164.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCellsCTClinical Trials
    108. Inhibition of the androgen receptor by mineralocorticoids at levels physiologically achieved in serum in patients treated with abiraterone acetate. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):292-9. Kim W, Jones JO, Diamond M, Haqq C, Molina A, Small EJ, Ryan CJ. PMID: 25047002.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    109. Time to disease-related pain and first opioid use in patients with metastatic castration-resistant prostate cancer treated with sipuleucel-T. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):259-64. Small EJ, Higano CS, Kantoff PW, Whitmore JB, Frohlich MW, Petrylak DP. PMID: 24957547.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    110. Prostate cancer, version 2.2014. J Natl Compr Canc Netw. 2014 May; 12(5):686-718. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kane CJ, Kawachi MH, Kuettel M, Kuzel TM, Lee RJ, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M, Rohren E, Rosenfeld S, Schaeffer E, Small EJ, Sonpavde G, Srinivas S, Stein C, Strope SA, Tward J, Shead DA, Ho M. PMID: 24812137.
      View in: PubMed   Mentions: 110     Fields:    Translation:Humans
    111. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J Natl Compr Canc Netw. 2014 May; 12(5):719-26. Aggarwal R, Zhang T, Small EJ, Armstrong AJ. PMID: 24812138.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    112. Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment. Clin Genitourin Cancer. 2014 Oct; 12(5):e167-72. Aggarwal R, Harris A, Formaker C, Small EJ, Molina A, Griffin TW, Ryan CJ. PMID: 24787968.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    113. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol. 2014 Nov; 66(5):815-25. Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, Shore ND, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Van Poppel H, Carles J, Flaig TW, Efstathiou E, Yu EY, Higano CS, Taplin ME, Griffin TW, Todd MB, Yu MK, Park YC, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ, Saad F. PMID: 24647231.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCTClinical Trials
    114. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol. 2014 Apr 10; 32(11):1143-50. Smith MR, Halabi S, Ryan CJ, Hussain A, Vogelzang N, Stadler W, Hauke RJ, Monk JP, Saylor P, Bhoopalam N, Saad F, Sanford B, Kelly WK, Morris M, Small EJ. PMID: 24590644.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCTClinical Trials
    115. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2014 Mar 01; 32(7):671-7. Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, Morris MJ, Small EJ. PMID: 24449231.
      View in: PubMed   Mentions: 84     Fields:    Translation:Humans
    116. Prostate cancer, version 1.2014. J Natl Compr Canc Netw. 2013 Dec 01; 11(12):1471-9. Mohler JL, Kantoff PW, Armstrong AJ, Bahnson RR, Cohen M, D'Amico AV, Eastham JA, Enke CA, Farrington TA, Higano CS, Horwitz EM, Kawachi MH, Kuettel M, Lee RJ, Macvicar GR, Malcolm AW, Miller D, Plimack ER, Pow-Sang JM, Richey S, Roach M, Rohren E, Rosenfeld S, Small EJ, Srinivas S, Stein C, Strope SA, Tward J, Walsh PC, Shead DA, Ho M. PMID: 24335682.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    117. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst. 2013 Nov 20; 105(22):1729-37. Halabi S, Lin CY, Small EJ, Armstrong AJ, Kaplan EB, Petrylak D, Sternberg CN, Shen L, Oudard S, de Bono J, Sartor O. PMID: 24136890.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    118. Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma. Cancer. 2014 Jan 01; 120(1):52-60. Halabi S, Rini B, Escudier B, Stadler WM, Small EJ. PMID: 24347384.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    119. Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. J Clin Oncol. 2013 Nov 01; 31(31):3944-50. Halabi S, Armstrong AJ, Sartor O, de Bono J, Kaplan E, Lin CY, Solomon NC, Small EJ. PMID: 24101043.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    120. Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate. Sci Transl Med. 2013 Aug 14; 5(198):198ra108. Nelson SJ, Kurhanewicz J, Vigneron DB, Larson PE, Harzstark AL, Ferrone M, van Criekinge M, Chang JW, Bok R, Park I, Reed G, Carvajal L, Small EJ, Munster P, Weinberg VK, Ardenkjaer-Larsen JH, Chen AP, Hurd RE, Odegardstuen LI, Robb FJ, Tropp J, Murray JA. PMID: 23946197.
      View in: PubMed   Mentions: 320     Fields:    Translation:Humans
    121. Reply to C.M. Booth et al. J Clin Oncol. 2013 Sep 10; 31(26):3300. Goodwin PJ, Ballman KV, Small EJ, Levine M, Cannistra SA. PMID: 23943837.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    122. The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). Cancer. 2013 Oct 15; 119(20):3636-43. Aggarwal R, Halabi S, Kelly WK, George D, Mahoney JF, Millard F, Stadler WM, Morris MJ, Kantoff P, Monk JP, Carducci M, Small EJ. PMID: 23913744.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    123. Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial. J Clin Oncol. 2013 Aug 01; 31(22):2791-8. Ryan CJ, Molina A, Li J, Kheoh T, Small EJ, Haqq CM, Grant RP, de Bono JS, Scher HI. PMID: 23816964.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    124. Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2013 May 01; 11(5):594-615. Clark PE, Spiess PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro L, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. PMID: 23667209.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    125. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013 Apr 04; 368(14):1314-25. Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM. PMID: 23550669.
      View in: PubMed   Mentions: 108     Fields:    Translation:Humans
    126. Bladder cancer. J Natl Compr Canc Netw. 2013 Apr 01; 11(4):446-75. Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, Inman BA, Kuban DA, Kuzel TM, Lele SM, Michalski J, Pagliaro LC, Pal SK, Patterson A, Plimack ER, Pohar KS, Porter MP, Richie JP, Sexton WJ, Shipley WU, Small EJ, Spiess PE, Trump DL, Wile G, Wilson TG, Dwyer M, Ho M. PMID: 23584347.
      View in: PubMed   Mentions: 100     Fields:    Translation:Humans
    127. Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer? Cancer Med. 2013 Apr; 2(2):243-52. Cha E, Small EJ. PMID: 23634292.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    128. Prognostic model for predicting survival of patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy. J Natl Cancer Inst. 2013 Apr 03; 105(7):499-503. Apolo AB, Ostrovnaya I, Halabi S, Iasonos A, Philips GK, Rosenberg JE, Riches J, Small EJ, Milowsky MI, Bajorin DF. PMID: 23411591.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    129. Evaluation of treatment benefit in Journal of Clinical Oncology. J Clin Oncol. 2013 Mar 20; 31(9):1123-4. Goodwin PJ, Ballman KV, Small EJ, Cannistra SA. PMID: 23358984.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    130. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013 Jan 10; 368(2):138-48. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE. PMID: 23228172.
      View in: PubMed   Mentions: 562     Fields:    Translation:Humans
    131. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol. 2013 Feb 01; 31(4):412-9. Smith DC, Smith MR, Sweeney C, Elfiky AA, Logothetis C, Corn PG, Vogelzang NJ, Small EJ, Harzstark AL, Gordon MS, Vaishampayan UN, Haas NB, Spira AI, Lara PN, Lin CC, Srinivas S, Sella A, Schöffski P, Scheffold C, Weitzman AL, Hussain M. PMID: 23169517.
      View in: PubMed   Mentions: 144     Fields:    Translation:HumansCTClinical Trials
    132. Diversity of antigen-specific responses induced in vivo with CTLA-4 blockade in prostate cancer patients. J Immunol. 2012 Oct 01; 189(7):3759-66. Kwek SS, Dao V, Roy R, Hou Y, Alajajian D, Simko JP, Small EJ, Fong L. PMID: 22956585.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    133. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol. 2012 Oct; 188(4):1164-9. Tangen CM, Hussain MH, Higano CS, Eisenberger MA, Small EJ, Wilding G, Donnelly BJ, Schelhammer PF, Crawford ED, Vogelzang NJ, Powell IJ, Thompson IM. PMID: 22921015.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    134. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst. 2012 Jul 18; 104(14):1107-9; author reply 1109-12. Kantoff PW, Higano CS, Small EJ, Whitmore JB, Frohlich MW, Schellhammer PF. PMID: 22825556.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    135. The future of cancer treatment: will it include immunotherapy? Cancer Cell. 2012 Jul 10; 22(1):7-8. Bluestone JA, Small EJ. PMID: 22789534.
      View in: PubMed   Mentions: 1     Fields:    
    136. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol. 2012 May 01; 30(13):1534-40. Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E, Vogelzang NJ, Small EJ. PMID: 22454414.
      View in: PubMed   Mentions: 181     Fields:    Translation:HumansCTClinical Trials
    137. Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782. Cancer. 2012 Sep 01; 118(17):4139-47. Monk JP, Halabi S, Picus J, Hussain A, Philips G, Kaplan E, Ahles T, Gu L, Vogelzang N, Kelly WK, Small EJ. PMID: 22180287.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    138. A phase II study of insulin-like growth factor receptor inhibition with nordihydroguaiaretic acid in men with non-metastatic hormone-sensitive prostate cancer. Oncol Rep. 2012 Jan; 27(1):3-9. Friedlander TW, Weinberg VK, Huang Y, Mi JT, Formaker CG, Small EJ, Harzstark AL, Lin AM, Fong L, Ryan CJ. PMID: 21971890.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    139. Prostate cancer: evolution or revolution? J Clin Oncol. 2011 Sep 20; 29(27):3595-8. Small EJ, de Bono JS. PMID: 21859996.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    140. Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809. Cancer. 2011 Dec 15; 117(24):5579-88. Hurwitz MD, Halabi S, Archer L, McGinnis LS, Kuettel MR, DiBiase SJ, Small EJ. PMID: 22535500.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    141. The relationship between symptomatology and treatment selection in metastatic castrate-resistant prostate cancer. Clin Adv Hematol Oncol. 2011 Jul; 9(7 Suppl 13):1-15. Small EJ, Penson DF, Sartor O. PMID: 22361784.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    142. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res. 2011 Jul 15; 17(14):4854-61. Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ. PMID: 21632851.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansCTClinical Trials
    143. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer. 2011 Sep 15; 117(18):4194-200. Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE. PMID: 21387258.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    144. Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium. Cancer. 2011 Jun 01; 117(11):2419-25. Harzstark AL, Rosenberg JE, Weinberg VK, Sharib J, Ryan CJ, Smith DC, Pagliaro LC, Beer TM, Liu G, Small EJ. PMID: 24048789.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    145. Bevacizumab and everolimus in renal cancer: a rational way forward. J Clin Oncol. 2010 Nov 20; 28(33):e692-3; author reply e694. Stadler WM, Phillips G, George DJ, Halabi S, Small E. PMID: 20940194.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    146. Effect of the somatostatin analog octreotide acetate on circulating insulin-like growth factor-1 and related peptides in patients with non-metastatic castration-resistant prostate cancer: results of a phase II study. Urol Oncol. 2012 Jul-Aug; 30(4):408-14. Friedlander TW, Weinberg VK, Small EJ, Sharib J, Harzstark AL, Lin AM, Fong L, Ryan CJ. PMID: 20884247.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    147. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer. 2011 Feb 01; 117(3):526-33. Picus J, Halabi S, Kelly WK, Vogelzang NJ, Whang YE, Kaplan EB, Stadler WM, Small EJ. PMID: 20862750.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    148. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29; 363(5):411-22. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF. PMID: 20818862.
      View in: PubMed   Mentions: 1405     Fields:    Translation:HumansCellsCTClinical Trials
    149. Sipuleucel-T. Nat Rev Drug Discov. 2010 Jul; 9(7):513-4. Higano CS, Small EJ, Schellhammer P, Yasothan U, Gubernick S, Kirkpatrick P, Kantoff PW. PMID: 20592741.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCells
    150. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010 May 01; 28(13):2137-43. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. PMID: 20368558.
      View in: PubMed   Mentions: 228     Fields:    Translation:HumansCTClinical Trials
    151. Castrate-resistant prostate cancer: therapeutic strategies. Expert Opin Pharmacother. 2010 Apr; 11(6):937-45. Harzstark AL, Small EJ. PMID: 20307219.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    152. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs. 2011 Dec; 29(6):1432-40. Bradley DA, Daignault S, Ryan CJ, Dipaola RS, Cooney KA, Smith DC, Small E, Mathew P, Gross ME, Stein MN, Chen A, Pienta KJ, Escara-Wilke J, Doyle G, Al-Hawary M, Keller ET, Hussain M. PMID: 20336348.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCellsCTClinical Trials
    153. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol. 2010 Mar 20; 28(9):1489-95. Reid AH, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LW, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de Bono JS. PMID: 20159823.
      View in: PubMed   Mentions: 150     Fields:    Translation:HumansCTClinical Trials
    154. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010 Mar 20; 28(9):1481-8. Ryan CJ, Smith MR, Fong L, Rosenberg JE, Kantoff P, Raynaud F, Martins V, Lee G, Kheoh T, Kim J, Molina A, Small EJ. PMID: 20159824.
      View in: PubMed   Mentions: 123     Fields:    Translation:HumansCTClinical Trials
    155. Developing immunotherapy as legitimate therapy for patients with prostate cancer. J Clin Oncol. 2010 Mar 01; 28(7):1085-7. Small EJ, Fong L. PMID: 20100956.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    156. Emerging biological observations in prostate cancer. Expert Rev Anticancer Ther. 2010 Jan; 10(1):89-101. Shah S, Small E. PMID: 20014889.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCells
    157. Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903). Clin Genitourin Cancer. 2009 Oct; 7(3):E66-70. Bajorin DF, Halabi S, Small E. PMID: 19815484.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    158. The mechanism of action of estrogen in castration-resistant prostate cancer: clues from hormone levels. Clin Genitourin Cancer. 2009 Oct; 7(3):E71-6. Aggarwal R, Weinberg V, Small EJ, Oh W, Rushakoff R, Ryan CJ. PMID: 19815485.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    159. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 01; 15(17):5569-75. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser MM. PMID: 19706807.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    160. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer. 2009 Aug 15; 115(16):3670-9. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW. PMID: 19536890.
      View in: PubMed   Mentions: 245     Fields:    Translation:HumansCTClinical Trials
    161. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol. 2009 Jun 10; 27(17):2766-71. Halabi S, Vogelzang NJ, Ou SS, Owzar K, Archer L, Small EJ. PMID: 19380448.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    162. Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol. 2009 May 20; 27(15):2450-6. Hussain M, Goldman B, Tangen C, Higano CS, Petrylak DP, Wilding G, Akdas AM, Small EJ, Donnelly BJ, Sundram SK, Burch PA, Dipaola RS, Crawford ED. PMID: 19380444.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    163. Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium. J Clin Oncol. 2009 Jun 10; 27(17):2772-8. Rosenberg JE, Ryan CJ, Weinberg VK, Smith DC, Hussain M, Beer TM, Ryan CW, Mathew P, Pagliaro LC, Harzstark AL, Sharib J, Small EJ. PMID: 19349545.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    164. Immunotherapeutics in development for prostate cancer. Oncologist. 2009 Apr; 14(4):391-8. Harzstark AL, Small EJ. PMID: 19342474.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    165. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol. 2009 Jun; 20(6):1074-9. Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ. PMID: 19168670.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    166. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res. 2009 Jan 15; 69(2):609-15. Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, Lin AM, Rosenberg J, Ryan CJ, Rini BI, Small EJ. PMID: 19147575.
      View in: PubMed   Mentions: 104     Fields:    Translation:HumansCellsCTClinical Trials
    167. Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research. Clin Genitourin Cancer. 2009 Jan; 7(1):51-7. Morris MJ, Basch EM, Wilding G, Hussain M, Carducci MA, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Slovin SF, Ryan C, Logothetis C, Scher HI. PMID: 19213669.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    168. Bladder cancer. J Natl Compr Canc Netw. 2009 Jan; 7(1):8-39. Montie JE, Clark PE, Eisenberger MA, El-Galley R, Greenberg RE, Herr HW, Hudes GR, Kuban DA, Kuzel TM, Lange PH, Lele SM, Michalski J, Patterson A, Pohar KS, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG. PMID: 19176203.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    169. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811. Cancer. 2008 Dec 01; 113(11):3137-45. Kelly WK, Halabi S, Elfiky A, Ou SS, Bogart J, Zelefsky M, Small E. PMID: 18989865.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    170. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008 Nov 20; 26(33):5422-8. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ. PMID: 18936475.
      View in: PubMed   Mentions: 276     Fields:    Translation:HumansCTClinical Trials
    171. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol. 2008 Nov 10; 26(32):5275-83. Fong L, Small EJ. PMID: 18838703.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansAnimals
    172. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy. J Urol. 2008 Nov; 180(5):2011-7; discussion 2017-8. Urba WJ, Nemunaitis J, Marshall F, Smith DC, Hege KM, Ma J, Nguyen M, Small EJ. PMID: 18801509.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    173. A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004. Clin Genitourin Cancer. 2008 Sep; 6(2):110-6. Dawson NA, Halabi S, Ou SS, Biggs DD, Kessinger A, Vogelzang N, Clamon GH, Nanus DM, Kelly WK, Small EJ. PMID: 18824434.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    174. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer. 2008 Sep 01; 113(5):975-84. Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman M, Simons JW, Sacks N, Aimi J, Small EJ. PMID: 18646045.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCellsCTClinical Trials
    175. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol. 2008 Sep; 180(3):860-5; discussion 865-6. Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R. PMID: 18635227.
      View in: PubMed   Mentions: 70     Fields:    Translation:Humans
    176. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood. 2008 Aug 15; 112(4):1175-83. Kavanagh B, O'Brien S, Lee D, Hou Y, Weinberg V, Rini B, Allison JP, Small EJ, Fong L. PMID: 18523152.
      View in: PubMed   Mentions: 80     Fields:    Translation:HumansCellsCTClinical Trials
    177. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol. 2008 May 20; 26(15):2544-9. Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA, Small EJ. PMID: 18487572.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    178. Prostate cancer update: 2007. Curr Opin Oncol. 2008 May; 20(3):294-9. Lin AM, Small EJ. PMID: 18391629.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    179. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809. Int J Radiat Oncol Biol Phys. 2008 Nov 01; 72(3):814-9. Hurwitz MD, Halabi S, Ou SS, McGinnis LS, Keuttel MR, Dibiase SJ, Small EJ. PMID: 18407435.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    180. Sipuleucel-T for the treatment of prostate cancer. Drugs Today (Barc). 2008 Apr; 44(4):271-8. Harzstark AL, Small EJ. PMID: 18536785.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    181. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008 Mar 01; 26(7):1148-59. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M. PMID: 18309951.
      View in: PubMed   Mentions: 597     Fields:    Translation:Humans
    182. p53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B Study (CALGB 9682). Urology. 2008 May; 71(5):933-7. D'Amico AV, Halabi S, Vollmer R, Loffredo M, McMahon E, Sanford B, Archer L, Vogelzang NJ, Small EJ, Kantoff PW. PMID: 18291508.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    183. Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207. Ann Oncol. 2008 May; 19(5):946-50. Rosenberg JE, Halabi S, Sanford BL, Himelstein AL, Atkins JN, Hohl RJ, Millard F, Bajorin DF, Small EJ. PMID: 18272914.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    184. A pilot dose-escalation study of the effects of nordihydroguareacetic acid on hormone and prostate specific antigen levels in patients with relapsed prostate cancer. BJU Int. 2008 Feb; 101(4):436-9. Ryan CJ, Harzstark AH, Rosenberg J, Lin A, Claros C, Goldfine ID, Kerner JF, Small EJ, Youngren JF. PMID: 18234062.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    185. Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study. Int J Radiat Oncol Biol Phys. 2008 May 01; 71(1):9-15. D'Amico AV, Halabi S, Tempany C, Titelbaum D, Philips GK, Loffredo M, McMahon E, Sanford B, Vogelzang NJ, Small EJ. PMID: 18037582.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    186. Phase II study of ketoconazole plus granulocyte-macrophage colony-stimulating factor for prostate cancer: effect of extent of disease on outcome. J Urol. 2007 Dec; 178(6):2372-6; discussion 2377. Ryan CJ, Weinberg V, Rosenberg J, Fong L, Lin A, Kim J, Small EJ. PMID: 17936834.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    187. A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102. BJU Int. 2008 Jan; 101(1):20-5. Philips GK, Halabi S, Sanford BL, Bajorin D, Small EJ. PMID: 17922873.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    188. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int. 2007 Oct; 100(4):765-9. Small EJ, Fontana J, Tannir N, DiPaola RS, Wilding G, Rubin M, Iacona RB, Kabbinavar FF. PMID: 17822457.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    189. Androgen-response elements in hormone-refractory prostate cancer: implications for treatment development. Lancet Oncol. 2007 Oct; 8(10):933-9. Hsieh AC, Small EJ, Ryan CJ. PMID: 17913662.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    190. Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. Cancer. 2007 Oct 01; 110(7):1478-84. Halabi S, Ou SS, Vogelzang NJ, Small EJ. PMID: 17665494.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    191. Management of hormone refractory prostate cancer. Curr Opin Support Palliat Care. 2007 Oct; 1(3):187-91. Lin AM, Small EJ. PMID: 18685361.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    192. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer. 2007 Aug 01; 110(3):556-63. Rosenberg JE, Weinberg VK, Kelly WK, Michaelson D, Hussain MH, Wilding G, Gross M, Hutcheon D, Small EJ. PMID: 17577218.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    193. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge). Expert Opin Biol Ther. 2007 Aug; 7(8):1275-80. Harzstark AL, Small EJ. PMID: 17696825.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    194. Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res. 2007 Jul 01; 13(13):3883-91. Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, Nelson WG, Ando D, Howard C, Borellini F, Nguyen M, Hege K, Simons JW. PMID: 17606721.
      View in: PubMed   Mentions: 74     Fields:    Translation:HumansCTClinical Trials
    195. A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer. Clin Genitourin Cancer. 2007 Jun; 5(5):323-8. Lin AM, Rini BI, Derynck MK, Weinberg V, Park M, Ryan CJ, Rosenberg JE, Bubley G, Small EJ. PMID: 17645829.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    196. Immunotherapy for prostate cancer. Curr Oncol Rep. 2007 May; 9(3):226-33. Fong L, Small EJ. PMID: 17430695.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    197. Prostate cancer update: 2006. Curr Opin Oncol. 2007 May; 19(3):229-33. Lin AM, Small EJ. PMID: 17414641.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    198. Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in patients with hormone refractory prostate cancer (HRPC). Invest New Drugs. 2007 Oct; 25(5):445-51. Ryan CJ, Stadler WM, Roth B, Hutcheon D, Conry S, Puchalski T, Morris C, Small EJ. PMID: 17458505.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    199. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Clin Cancer Res. 2007 Apr 01; 13(7):2030-7. Ryan CJ, Halabi S, Ou SS, Vogelzang NJ, Kantoff P, Small EJ. PMID: 17404083.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    200. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res. 2007 Mar 15; 13(6):1810-5. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. PMID: 17363537.
      View in: PubMed   Mentions: 122     Fields:    Translation:HumansCTClinical Trials
    201. Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancer. BJU Int. 2007 Mar; 99(3):519-24. Garcia JA, Rosenberg JE, Weinberg V, Scott J, Frohlich M, Park JW, Small EJ. PMID: 17407512.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    202. Expression of insulin-like growth factor-1 receptor in local and metastatic prostate cancer. Urol Oncol. 2007 Mar-Apr; 25(2):134-40. Ryan CJ, Haqq CM, Simko J, Nonaka DF, Chan JM, Weinberg V, Small EJ, Goldfine ID. PMID: 17349528.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    203. The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials. J Urol. 2007 Feb; 177(2):531-4. Halabi S, Vogelzang NJ, Ou SS, Small EJ. PMID: 17222627.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    204. Intermittent chemotherapy for metastatic hormone refractory prostate cancer. Crit Rev Oncol Hematol. 2007 Mar; 61(3):243-54. Lin AM, Ryan CJ, Small EJ. PMID: 17161610.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    205. The case for secondary hormonal therapies in the chemotherapy age. J Urol. 2006 Dec; 176(6 Pt 2):S66-71. Small EJ, Ryan CJ. PMID: 17084172.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    206. Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: a cancer and leukemia group B study. Cancer. 2006 Dec 01; 107(11):2706-14. Kornblith AB, Dowell JM, Herndon JE, Engelman BJ, Bauer-Wu S, Small EJ, Morrison VA, Atkins J, Cohen HJ, Holland JC. PMID: 17078057.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    207. High risk biochemical relapse and the timing of androgen deprivation therapy. J Urol. 2006 Dec; 176(6 Pt 2):S61-5. Ryan CJ, Small EJ. PMID: 17084171.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    208. Bladder cancer. Clinical guidelines in oncology. J Natl Compr Canc Netw. 2006 Nov; 4(10):984-1014. Montie JE, Abrahams NA, Bahnson RR, Eisenberger MA, El-Galley R, Herr HW, Hudes GR, Kuzel TM, Lange PH, Patterson A, Pollack A, Richie JP, Sexton WJ, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG. PMID: 17112448.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    209. A phase II trial of imatinib mesylate in patients with biochemical relapse of prostate cancer after definitive local therapy. BJU Int. 2006 Oct; 98(4):763-9. Lin AM, Rini BI, Weinberg V, Fong K, Ryan CJ, Rosenberg JE, Fong L, Small EJ. PMID: 16796694.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    210. A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008. Cancer. 2006 Sep 15; 107(6):1273-9. Stadler WM, Halabi S, Rini B, Ernstoff MS, Davila E, Picus J, Barrier R, Small EJ. PMID: 16909426.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    211. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Urol Oncol. 2006 Sep-Oct; 24(5):396-402. Ryan CJ, Elkin EP, Small EJ, Duchane J, Carroll P. PMID: 16962488.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    212. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urol Oncol. 2006 Sep-Oct; 24(5):434-41. Lin AM, Hershberg RM, Small EJ. PMID: 16962496.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    213. Androgen deprivation therapy in locally advanced and metastatic prostate cancer. Minerva Urol Nefrol. 2006 Sep; 58(3):119-26. Ryan CJ, Small EJ. PMID: 17124482.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    214. Sipuleucel-T (APC8015) for prostate cancer. Expert Rev Anticancer Ther. 2006 Sep; 6(9):1163-7. So-Rosillo R, Small EJ. PMID: 17020451.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    215. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol. 2006 Aug 20; 24(24):3984-90. Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D. PMID: 16921051.
      View in: PubMed   Mentions: 112     Fields:    Translation:Humans
    216. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status. BJU Int. 2006 Oct; 98(4):756-62. Rini BI, Jaeger E, Weinberg V, Sein N, Chew K, Fong K, Simko J, Small EJ, Waldman FM. PMID: 16827904.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    217. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006 Jul 01; 24(19):3089-94. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, Verjee SS, Jones LA, Hershberg RM. PMID: 16809734.
      View in: PubMed   Mentions: 296     Fields:    Translation:HumansCTClinical Trials
    218. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer. 2006 Jul 01; 107(1):67-74. Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. PMID: 16736512.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCellsCTClinical Trials
    219. Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. J Urol. 2006 Jul; 176(1):81-6. Halabi S, Vogelzang NJ, Ou SS, Kelly WK, Small EJ. PMID: 16753374.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    220. Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. Biol Blood Marrow Transplant. 2006 Jul; 12(7):778-85. Rini BI, Halabi S, Barrier R, Margolin KA, Avigan D, Logan T, Stadler WM, McCarthy PL, Linker CA, Small EJ. PMID: 16785067.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    221. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. J Urol. 2006 Jun; 175(6):2087-91. Rini BI, Fong L, Weinberg V, Kavanaugh B, Small EJ. PMID: 16697809.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    222. Activities and accomplishments of the cancer and leukemia group B genitourinary committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3596s-600s. Small EJ, Halabi S, Kantoff P, D'Amico A, Stadler W, Kelley WK, Mohler J, Bajorin D, Vogelzang NJ. PMID: 16740791.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    223. A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer. Mol Ther. 2006 Jul; 14(1):107-17. Small EJ, Carducci MA, Burke JM, Rodriguez R, Fong L, van Ummersen L, Yu DC, Aimi J, Ando D, Working P, Kirn D, Wilding G. PMID: 16690359.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansCellsCTClinical Trials
    224. Immunotherapy for prostate cancer. Curr Urol Rep. 2006 May; 7(3):239-46. Fong L, Small EJ. PMID: 16630528.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    225. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: history and rationale. Urol Oncol. 2006 May-Jun; 24(3):250-3. Ryan CJ, Lin AM, Small EJ. PMID: 16678059.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    226. Clinical trials in patients with biochemically relapsed prostate cancer. BJU Int. 2006 May; 97(5):905-10. Lin AM, Rini BI, Small EJ. PMID: 16643469.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    227. Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer. Cancer. 2006 May 01; 106(9):1917-24. Wilding G, Soulie P, Trump D, Das-Gupta A, Small E. PMID: 16568471.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    228. Prostate cancer update: 2005. Curr Opin Oncol. 2006 May; 18(3):284-8. Ryan CJ, Small EJ. PMID: 16552242.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    229. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006 Apr 19; 98(8):516-21. Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. PMID: 16622120.
      View in: PubMed   Mentions: 68     Fields:    Translation:Humans
    230. Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480. Clin Genitourin Cancer. 2006 Mar; 4(4):269-74. Humphrey PA, Halabi S, Picus J, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW. PMID: 16729910.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    231. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer. 2006 Feb 01; 106(3):566-75. Rini BI, Weinberg V, Dunlap S, Elchinoff A, Yu N, Bok R, Simko J, Small EJ. PMID: 16369983.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    232. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. Cancer. 2006 Jan 01; 106(1):58-62. Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, Small EJ. PMID: 16329138.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    233. Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Leukemia Group B study. Clin Cancer Res. 2005 Nov 15; 11(22):8109-13. Ross RW, Halabi S, Ou SS, Rajeshkumar BR, Woda BA, Vogelzang NJ, Small EJ, Taplin ME, Kantoff PW. PMID: 16299243.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    234. Early versus delayed androgen deprivation for prostate cancer: new fuel for an old debate. J Clin Oncol. 2005 Nov 10; 23(32):8225-31. Ryan CJ, Small EJ. PMID: 16278477.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    235. Prostate cancer immunology: biology, therapeutics, and challenges. J Clin Oncol. 2005 Nov 10; 23(32):8262-9. Webster WS, Small EJ, Rini BI, Kwon ED. PMID: 16278482.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    236. Phase II trial of carboplatin and paclitaxel in cisplatin-pretreated advanced transitional cell carcinoma: a Southwest Oncology Group study. Cancer. 2005 Oct 15; 104(8):1627-32. Vaishampayan UN, Faulkner JR, Small EJ, Redman BG, Keiser WL, Petrylak DP, Crawford ED. PMID: 16138364.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    237. Prior estrogen therapy as a predictor of response to subsequent estramustine-based chemotherapy in patients with androgen-independent prostate cancer. Clin Prostate Cancer. 2005 Sep; 4(2):113-7. Garcia JA, Weinberg V, Small EJ. PMID: 16197612.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    238. Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 study. Urology. 2005 Aug; 66(2):386-91. Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW. PMID: 16098367.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    239. Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy. Clin Cancer Res. 2005 Jul 15; 11(14):5195-8. Ross RW, Manola J, Hennessy K, Galsky M, Scher H, Small E, Kelly WK, Kantoff PW. PMID: 16033836.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    240. Update on chemotherapy for advanced bladder cancer. J Urol. 2005 Jul; 174(1):14-20. Rosenberg JE, Carroll PR, Small EJ. PMID: 15947569.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    241. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. J Clin Oncol. 2005 Jun 01; 23(16):3726-32. Stadler WM, Rosner G, Small E, Hollis D, Rini B, Zaentz SD, Mahoney J, Ratain MJ. PMID: 15923569.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    242. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer. 2005 Jun; 4(1):55-60. Beinart G, Rini BI, Weinberg V, Small EJ. PMID: 15992463.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsCTClinical Trials
    243. A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma. Cancer. 2005 May 15; 103(10):2035-41. Rosenberg JE, von der Maase H, Seigne JD, Mardiak J, Vaughn DJ, Moore M, Sahasrabudhe D, Palmer PA, Perez-Ruixo JJ, Small EJ. PMID: 15812833.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    244. Progress in detection and treatment of prostate cancer. Curr Opin Oncol. 2005 May; 17(3):257-60. Ryan CJ, Small EJ. PMID: 15818171.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    245. Secondary hormonal manipulations in prostate cancer. Curr Oncol Rep. 2005 May; 7(3):228-33. Ryan CJ, Small EJ. PMID: 15847715.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    246. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol. 2005 May 01; 23(13):2918-25. Smith MR, Kabbinavar F, Saad F, Hussain A, Gittelman MC, Bilhartz DL, Wynne C, Murray R, Zinner NR, Schulman C, Linnartz R, Zheng M, Goessl C, Hei YJ, Small EJ, Cook R, Higano CS. PMID: 15860850.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansCTClinical Trials
    247. Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancer. J Clin Oncol. 2005 Apr 01; 23(10):2434-5; author reply 2435. Halabi S, Small EJ, Vogelzang NJ. PMID: 15800342.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    248. High-dose etoposide, thiotepa, and dose-adjusted carboplatin (TVCa) with autologous hematopoietic stem cell rescue as treatment of relapsed or refractory germ cell cancer. Am J Clin Oncol. 2005 Apr; 28(2):130-7. Chaudhary UB, Damon LE, Rugo HS, Linker CA, Navarro W, Small EJ. PMID: 15803005.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    249. The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. Clin Cancer Res. 2005 Mar 01; 11(5):1815-20. George DJ, Halabi S, Shepard TF, Sanford B, Vogelzang NJ, Small EJ, Kantoff PW. PMID: 15756004.
      View in: PubMed   Mentions: 45     Fields:    Translation:Humans
    250. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol. 2005 Mar 01; 23(7):1439-46. Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK. PMID: 15735119.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    251. Lifestyle correlates of health perception and treatment satisfaction in a clinical cohort of men with prostate cancer. Clin Prostate Cancer. 2005 Mar; 3(4):239-45. Sheriff SK, Shohara RA, Dumican SB, Small EJ, Carroll PR, Chan JM. PMID: 15882480.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    252. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma. Cancer. 2005 Feb 01; 103(3):553-8. Rini BI, Weinberg V, Small EJ. PMID: 15612026.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    253. Kinetics of development and characteristics of antibodies induced in cancer patients against yeast expressed rDNA derived granulocyte macrophage colony stimulating factor (GM-CSF). Cytokine. 2005 Jan 21; 29(2):56-66. Rini B, Wadhwa M, Bird C, Small E, Gaines-Das R, Thorpe R. PMID: 15598439.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    254. Bladder cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2005 Jan; 3(1):4-5, 19-34. Montie JE, Bahnson RR, Cohen SM, Drucker B, Eisenberger MA, El-Galley R, Herr HW, Hudes GR, Kuzel TM, Lange PH, Patterson A, Pollack A, Richie JP, Seigne J, Shipley WU, Small EJ, Trump DL, Walther PJ, Wilson TG. PMID: 19813320.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    255. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer. 2004 Nov 15; 101(10):2202-8. Ahles TA, Herndon JE, Small EJ, Vogelzang NJ, Kornblith AB, Ratain MJ, Stadler W, Palchak D, Marshall ME, Wilding G, Petrylak D, Holland JC. PMID: 15484217.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    256. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol. 2005 Feb 10; 23(5):1028-43. Rini BI, Small EJ. PMID: 15534359.
      View in: PubMed   Mentions: 76     Fields:    Translation:Humans
    257. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 Oct 07; 351(15):1513-20. Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. PMID: 15470214.
      View in: PubMed   Mentions: 928     Fields:    Translation:HumansCTClinical Trials
    258. Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. Cancer. 2004 Oct 01; 101(7):1569-74. Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Spiegelman B, Small E, Kantoff PW. PMID: 15468186.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    259. Second-line chemotherapy for hormone-refractory prostate cancer: has the time come? Clin Prostate Cancer. 2004 Sep; 3(2):122-4. Rosenberg JE, Small EJ. PMID: 15479496.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    260. 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901. Urol Oncol. 2004 Sep-Oct; 22(5):398-403. Amin A, Halabi S, Gelmann EP, Stadler W, Vogelzang N, Small E. PMID: 15464920.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    261. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol. 2004 Sep 15; 22(18):3705-12. Oh WK, Kantoff PW, Weinberg V, Jones G, Rini BI, Derynck MK, Bok R, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ. PMID: 15289492.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    262. Impact of race on survival in men with metastatic hormone-refractory prostate cancer. Urology. 2004 Aug; 64(2):212-7. Halabi S, Small EJ, Vogelzang NJ, Barrier RC, George SL, Gilligan TD. PMID: 15302462.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    263. Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinoma. Cancer. 2004 Jul 01; 101(1):90-5. Rini BI, Weinberg V, Shaw V, Scott J, Bok R, Park JW, Small EJ. PMID: 15221993.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    264. Monoclonal antibody therapy for prostate cancer: finally a reality? J Clin Oncol. 2004 Jul 01; 22(13):2515-6. Small EJ. PMID: 15173211.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    265. Practice and progress in kidney cancer: methodology for novel drug development. J Urol. 2004 Jun; 171(6 Pt 1):2115-21. Rini BI, Weinberg V, Small EJ. PMID: 15126769.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    266. Advances in prostate cancer. Curr Opin Oncol. 2004 May; 16(3):242-6. Ryan CJ, Small EJ. PMID: 15069320.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    267. The selection of hormonal therapy in prostate cancer: who, when, and for how long? J Natl Compr Canc Netw. 2004 May; 2(3):261-8. Ryan CJ, Small EJ. PMID: 19795609.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    268. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res. 2004 Apr 15; 10(8):2584-6. Rini BI, Halabi S, Taylor J, Small EJ, Schilsky RL. PMID: 15102658.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    269. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol. 2004 Mar 15; 22(6):1025-33. Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ. PMID: 15020604.
      View in: PubMed   Mentions: 147     Fields:    Translation:HumansCTClinical Trials
    270. Safety and biological activity of repeated doses of recombinant human Flt3 ligand in patients with bone scan-negative hormone-refractory prostate cancer. Clin Cancer Res. 2004 Feb 15; 10(4):1219-25. Higano CS, Vogelzang NJ, Sosman JA, Feng A, Caron D, Small EJ. PMID: 14977818.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCellsCTClinical Trials
    271. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 2004 Feb 01; 22(3):537-56. Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR. PMID: 14752077.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    272. Role of secondary hormonal therapy in the management of recurrent prostate cancer. Urology. 2003 Dec 29; 62 Suppl 1:87-94. Ryan CJ, Small EJ. PMID: 14747046.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    273. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology. 2003 Dec 29; 62 Suppl 1:55-62. Eastham JA, Kelly WK, Grossfeld GD, Small EJ. PMID: 14747042.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCTClinical Trials
    274. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer. 2003 Dec 15; 98(12):2592-8. Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Small EJ. PMID: 14669278.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    275. The evolving role of androgen deprivation therapy in the management of prostate cancer. Minerva Urol Nefrol. 2003 Dec; 55(4):219-38. Cooperberg MR, Small EJ, D'Amico A, Carroll PR. PMID: 14765015.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    276. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003 Dec 01; 21(23):4277-84. Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO. PMID: 14581438.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCTClinical Trials
    277. Immunotherapy for prostate cancer. Semin Oncol. 2003 Oct; 30(5):649-58. Fong L, Small EJ. PMID: 14571412.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    278. Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol. 2003 Jul 15; 21(14):2673-8. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ. PMID: 12860943.
      View in: PubMed   Mentions: 91     Fields:    Translation:HumansCellsCTClinical Trials
    279. The potential for prostate cancer immunotherapy. Crit Rev Oncol Hematol. 2003 Jun 27; 46 Suppl:S117-25. Rini BI, Small EJ. PMID: 12850532.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    280. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res. 2003 Jun; 9(6):2040-8. LoRusso PM, Herbst RS, Rischin D, Ranson M, Calvert H, Raymond E, Kieback D, Kaye S, Gianni L, Harris A, Bjork T, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Feyereislova A, Heyes A, Averbuch SD, Ochs J, Baselga J. PMID: 12796366.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    281. Prostate cancer update. Curr Opin Oncol. 2003 May; 15(3):217-21. Rosenberg J, Small EJ. PMID: 12778015.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    282. Overview of bladder cancer trials in the Cancer and Leukemia Group B. Cancer. 2003 Apr 15; 97(8 Suppl):2090-8. Small EJ, Halabi S, Dalbagni G, Pruthi R, Phillips G, Edelman M, Bajorin D. PMID: 12673701.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    283. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003 Apr 01; 21(7):1232-7. Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, Levine EG, Blumenstein BA, Vogelzang NJ. PMID: 12663709.
      View in: PubMed   Mentions: 185     Fields:    Translation:Humans
    284. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. J Clin Oncol. 2003 Feb 01; 21(3):490-5. Halabi S, Small EJ, Hayes DF, Vogelzang NJ, Kantoff PW. PMID: 12560440.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    285. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol. 2003 Jan 01; 21(1):99-105. Rini BI, Weinberg V, Bok R, Small EJ. PMID: 12506177.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    286. Complementary and alternative therapies in prostate cancer. Semin Oncol. 2002 Dec; 29(6):575-84. Oh WK, Small EJ. PMID: 12516040.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    287. Bloodborne biomolecular markers in prostate cancer development and progression. Nat Rev Cancer. 2002 Dec; 2(12):918-26. Bok RA, Small EJ. PMID: 12459730.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    288. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol. 2002 Oct 01; 20(19):3972-82. Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K, Kelly WK, Kattan MW. PMID: 12351594.
      View in: PubMed   Mentions: 97     Fields:    Translation:Humans
    289. Hormone-refractory Prostate Cancer. Curr Treat Options Oncol. 2002 Oct; 3(5):437-46. Rini BI, Small EJ. PMID: 12194808.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    290. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol. 2002 Sep 15; 20(18):3815-25. Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM. PMID: 12228201.
      View in: PubMed   Mentions: 93     Fields:    Translation:HumansCTClinical Trials
    291. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. J Clin Oncol. 2002 Aug 15; 20(16):3369-75. Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. PMID: 12177096.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    292. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol. 2002 Aug; 168(2):542-5. Harris KA, Weinberg V, Bok RA, Kakefuda M, Small EJ. PMID: 12131305.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    293. Neoadjuvant strategies for prostate cancer prior to radical prostatectomy. Semin Urol Oncol. 2002 Aug; 20(3 Suppl 1):10-8. Meng MV, Grossfeld GD, Carroll PR, Small EJ. PMID: 12198633.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    294. Secondary hormonal manipulation of prostate cancer. Semin Urol Oncol. 2002 Aug; 20(3 Suppl 1):24-30. Small EJ, Harris KA. PMID: 12198635.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    295. Prostate-specific antigen in prostate cancer: a case study in the development of a tumor marker to monitor recurrence and assess response. Semin Oncol. 2002 Jun; 29(3):264-73. Small EJ, Roach M. PMID: 12063679.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    296. Liposomal doxorubicin for the treatment of hormone-refractory prostate cancer. Clin Prostate Cancer. 2002 Jun; 1(1):37-41. Harris KA, Harney E, Small EJ. PMID: 15046711.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    297. Prostate cancer update. Curr Opin Oncol. 2002 May; 14(3):286-91. Rini BI, Small EJ. PMID: 11981273.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    298. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer. J Urol. 2002 May; 167(5):1952-6. Ross RW, Small EJ. PMID: 11956415.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    299. PC-SPES and prostate cancer. Urol Clin North Am. 2002 Feb; 29(1):59-66, viii. Oh WK, Small EJ. PMID: 12109356.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    300. Immunotherapy for prostate cancer. Curr Oncol Rep. 2001 Sep; 3(5):418-23. Rini BI, Small EJ. PMID: 11489243.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    301. Intermittent androgen deprivation: update of cycling characteristics in patients without clinically apparent metastatic prostate cancer. Urology. 2001 Aug; 58(2):240-5. Grossfeld GD, Chaudhary UB, Reese DM, Carroll PR, Small EJ. PMID: 11489710.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    302. HER2 protein expression and gene amplification in androgen-independent prostate cancer. Am J Clin Pathol. 2001 Aug; 116(2):234-9. Reese DM, Small EJ, Magrane G, Waldman FM, Chew K, Sudilovsky D. PMID: 11488070.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    303. Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy. Urology. 2001 Aug; 58(2 Suppl 1):56-64. Grossfeld GD, Small EJ, Lubeck DP, Latini D, Broering JM, Carroll PR. PMID: 11502450.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    304. Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer. Semin Oncol. 2001 Aug; 28(4 Suppl 15):71-6. Small EJ, Bok R, Reese DM, Sudilovsky D, Frohlich M. PMID: 11685733.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    305. Secondary hormonal manipulation of prostate cancer. Curr Urol Rep. 2001 Jun; 2(3):224-30. Harris KA, Small EJ. PMID: 12084269.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    306. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study. Cancer Res. 2001 Mar 15; 61(6):2533-6. Bok RA, Halabi S, Fei DT, Rodriquez CR, Hayes DF, Vogelzang NJ, Kantoff P, Shuman MA, Small EJ. PMID: 11289126.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    307. Hormonal treatment for prostate cancer. Expert Opin Investig Drugs. 2001 Mar; 10(3):493-510. Harris KA, Small EJ. PMID: 11227048.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    308. Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival. J Clin Oncol. 2001 Mar 01; 19(5):1304-11. Small EJ, McMillan A, Meyer M, Chen L, Slichenmyer WJ, Lenehan PF, Eisenberger M. PMID: 11230472.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    309. Docetaxel in prostate cancer. Anticancer Drugs. 2001 Feb; 12 Suppl 1:S17-20. Small EJ. PMID: 11340899.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    310. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol. 2000 Dec 01; 18(23):3894-903. Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH. PMID: 11099318.
      View in: PubMed   Mentions: 139     Fields:    Translation:HumansCellsCTClinical Trials
    311. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol. 2000 Nov 01; 18(21):3595-603. Small EJ, Frohlich MW, Bok R, Shinohara K, Grossfeld G, Rozenblat Z, Kelly WK, Corry M, Reese DM. PMID: 11054432.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    312. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol. 2000 Jul; 18(13):2537-44. Small EJ, Lew D, Redman BG, Petrylak DP, Hammond N, Gross HM, Eastham JA, Crawford ED. PMID: 10893284.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    313. Management of a positive surgical margin after radical prostatectomy: decision analysis. J Urol. 2000 Jul; 164(1):93-9; discussion 100. Grossfeld GD, Tigrani VS, Nudell D, Roach M, Weinberg VK, Presti JC, Small EJ, Carroll PR. PMID: 10840431.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    314. An update on prostate cancer research. Curr Opin Oncol. 2000 May; 12(3):265-72. Small EJ, Reese DM. PMID: 10841200.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    315. A phase II pilot study of KW-2189 in patients with advanced renal cell carcinoma. Invest New Drugs. 2000 May; 18(2):193-7. Small EJ, Figlin R, Petrylak D, Vaughn DJ, Sartor O, Horak I, Pincus R, Kremer A, Bowden C. PMID: 10857997.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    316. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol. 2000 Apr; 18(7):1440-50. Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, Lenehan PF, Chen L, Slichenmyer WJ, Eisenberger M. PMID: 10735891.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCTClinical Trials
    317. Infusional floxuridine-based therapy for patients with metastatic renal cell carcinoma. Cancer. 2000 Mar 15; 88(6):1310-6. Reese DM, Corry M, Small EJ. PMID: 10717611.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    318. New treatment strategies in advanced prostate cancer. Radiol Clin North Am. 2000 Jan; 38(1):203-11, ix-x. Small EJ, Reese DM. PMID: 10664673.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    319. Potential role of nephrectomy in the treatment of metastatic renal cell carcinoma: a retrospective analysis. Urology. 2000 Jan; 55(1):36-40. Tigrani VS, Reese DM, Small EJ, Presti JC, Carroll PR. PMID: 10654891.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    320. Outpatient combination chemoimmunotherapy for patients with metastatic melanoma. Results of a phase I/II trial. Cancer. 1999 Nov 15; 86(10):2160-5. Kashani-Sabet M, Sagebiel RW, Collins HE, Glassberg AB, Allen RE, Leong SP, Small EJ. PMID: 10570447.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    321. Hormone-refractory prostate cancer: an evolving standard of care. Semin Oncol. 1999 Oct; 26(5 Suppl 17):61-7. Small EJ, Reese DM, Vogelzang NJ. PMID: 10604272.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    322. Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res. 1999 Jul; 5(7):1738-44. Small EJ, Reese DM, Um B, Whisenant S, Dixon SC, Figg WD. PMID: 10430077.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    323. Secondary hormonal manipulations in hormone refractory prostate cancer. Urol Clin North Am. 1999 May; 26(2):311-21, viii. Reese DM, Small EJ. PMID: 10361554.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    324. Advances in prostate cancer. Curr Opin Oncol. 1999 May; 11(3):226-35. Small EJ. PMID: 10328599.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    325. The treatment of advanced prostate cancer with ketoconazole: safety issues. Drug Saf. 1999 May; 20(5):451-8. Bok RA, Small EJ. PMID: 10348095.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    326. Diffuse retroperitoneal amyloidosis due to renal cell carcinoma. Br J Radiol. 1999 Apr; 72(856):412-3. Coakley FV, Hricak H, Presti JC, Small EJ. PMID: 10474508.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    327. Stage II nonseminomatous testis cancer: the roles of primary and adjuvant chemotherapy. Urol Clin North Am. 1998 Aug; 25(3):451-9. Frohlich MW, Small EJ. PMID: 9728214.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    328. Long-term side effects of treatment for testis cancer. Urol Clin North Am. 1998 Aug; 25(3):503-15. Grossfeld GD, Small EJ. PMID: 9728220.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    329. Prostate cancer, Incidence, management and outcomes. Drugs Aging. 1998 Jul; 13(1):71-81. Small EJ. PMID: 9679210.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    330. Update on the diagnosis and treatment of prostate cancer. Curr Opin Oncol. 1998 May; 10(3):244-52. Small EJ. PMID: 9619361.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    331. The treatment of metastatic renal cell carcinoma patients with recombinant human gamma interferon. Cancer J Sci Am. 1998 May-Jun; 4(3):162-7. Small EJ, Weiss GR, Malik UK, Walther PJ, Johnson D, Wilding G, Kuzel T, Bajamonde A, Paton V. PMID: 9612597.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    332. Intermittent androgen deprivation for clinically localized prostate cancer: initial experience. Urology. 1998 Jan; 51(1):137-44. Grossfeld GD, Small EJ, Carroll PR. PMID: 9457309.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    333. Pyrazoloacridine for the treatment of hormone-refractory prostate cancer. Cancer Invest. 1998; 16(7):456-61. Small EJ, Fippin LJ, Whisenant SP. PMID: 9774952.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    334. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer. 1997 Nov 01; 80(9):1755-9. Small EJ, Baron A, Bok R. PMID: 9351544.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    335. Prostate cancer. Curr Opin Oncol. 1997 May; 9(3):277-86. Small EJ. PMID: 9229151.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    336. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol. 1997 Apr; 157(4):1204-7. Small EJ, Baron AD, Fippin L, Apodaca D. PMID: 9120902.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    337. Focal therapy for prostate cancer 1996: maximizing outcome. Urology. 1997 Mar; 49(3A Suppl):84-94. Carroll PR, Presti JC, Small E, Roach M. PMID: 9123742.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    338. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol. 1997 Jan; 15(1):382-8. Small EJ, Vogelzang NJ. PMID: 8996165.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    339. Cancer and Leukemia Group B trials for advanced prostate cancer. Semin Oncol. 1996 Dec; 23(6 Suppl 14):28-31. Small EJ, Dawson NA, Kantoff PW, Vogelzang NJ. PMID: 8996582.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    340. Radiotherapy for high grade clinically localized adenocarcinoma of the prostate. J Urol. 1996 Nov; 156(5):1719-23. Roach M, Meehan S, Kroll S, Weil M, Ryu J, Small EJ, Margolis LW, Presti J, Carroll PC, Phillips TL. PMID: 8863578.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    341. A carboplatin-based regimen for the treatment of patients with advanced transitional cell carcinoma of the urothelium. Cancer. 1996 Oct 15; 78(8):1775-80. Small EJ, Fippin LJ, Ernest ML, Carroll PR. PMID: 8859191.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    342. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res. 1996 Jul 01; 56(13):3091-102. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensen RH. PMID: 8674067.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCells
    343. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer. 1995 Oct 15; 76(8):1428-34. Small EJ, Srinivas S. PMID: 8620419.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    344. Malignant germ cell tumors in men infected with the human immunodeficiency virus: natural history and results of therapy. J Clin Oncol. 1995 Jun; 13(6):1391-7. Timmerman JM, Northfelt DW, Small EJ. PMID: 7538557.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    345. A phase I/II study of alternating constant rate infusion floxuridine with constant rate infusion vinblastine for the treatment of metastatic renal cell carcinoma. Cancer. 1994 Jun 01; 73(11):2803-7. Small EJ, Frye JW, Wilkinson MJ, Carroll PR, Ernest ML, Stagg RJ. PMID: 8194022.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    346. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology. 1994 Mar; 43(3):408-10. Small EJ, Carroll PR. PMID: 7510915.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    347. Nephrectomy for metastatic renal cell carcinoma: a component of systemic treatment regimens. J Surg Oncol. 1994 Jan; 55(1):7-13. Wolf JS, Aronson FR, Small EJ, Carroll PR. PMID: 8289458.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    348. Prostate cancer: who to screen, and what the results mean. Geriatrics. 1993 Dec; 48(12):28-30, 35-8. Small EJ. PMID: 7504646.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    349. Gallium-avid thymic hyperplasia in an adult after chemotherapy for Hodgkin disease. Cancer. 1993 Aug 01; 72(3):905-8. Small EJ, Venook AP, Damon LE. PMID: 8334644.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    350. A phase II study of constant-infusion floxuridine for the treatment of metastatic renal cell carcinoma. Cancer. 1993 Jun 01; 71(11):3601-4. Wilkinson MJ, Frye JW, Small EJ, Venook AP, Carroll PR, Ernest ML, Stagg RJ. PMID: 8490909.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    Eric's Networks
    Concepts (703)
    Derived automatically from this person's publications.
    _
    Co-Authors (117)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _